Glydam XR 500
Dapagliflozin plus extended-release metformin for glucose, heart, and kidney protection.
“Better sugar control. Stronger heart. Protected kidneys.”
Composition
- Active ingredients
- Dapagliflozin 10 mg + Metformin Hydrochloride (Extended-Release) 500 mg
- Dosage form
- Extended-release tablets
- Pack size
- 10x3 tablets
Indications
- Type 2 Diabetes Mellitus
- Heart Failure (HFrEF)
- Chronic Kidney Disease
- Overweight diabetic patients
Dosage snapshot
- Dapagliflozin
- 10 mg once daily
- Metformin ER starting dose
- 500 mg, titrate gradually
- Maximum metformin dose
- 2000 mg per day
Dosage should be individualised by the prescribing physician.
Key benefits
- Dual mechanism combining kidney and liver glucose control.
- Cardio-renal protection, reducing cardiovascular and kidney risks.
- Supports weight and blood pressure alongside metabolic health.
- Once-daily convenience improves compliance.
Why this formula works
Glydam XR pairs an SGLT2 inhibitor with extended-release metformin to act on glucose from two directions at once: dapagliflozin increases renal glucose excretion, while metformin ER reduces hepatic glucose output and improves insulin sensitivity.
Because dapagliflozin also carries independent cardio-renal benefits, this combination is positioned for the type 2 diabetic patient who needs more than glycaemic control alone — particularly those with coexisting heart failure, chronic kidney disease, or excess weight — while the extended-release metformin format is chosen to support gastrointestinal tolerability over once-daily dosing.